Which has the lower trailing P/E, BSX or GSK?

GSK has the lower trailing P/E: BSX trades at 20.51 and GSK at 16.49. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BSX or GSK?

Over the past five years, BSX grew revenue faster — BSX at a 13.40% CAGR versus GSK at 1.38%.

Does BSX or GSK pay a bigger dividend?

GSK pays a dividend (3.44% yield), while BSX has no payments in the available dividend history.

Is BSX or GSK more profitable?

BSX runs the higher net margin — BSX at 17.47% versus GSK at 14.52%.

How have BSX and GSK total returns compared?

Over the past 10 years, BSX delivered 7.77% and GSK delivered 6.47% annualized total return. Past performance doesn't predict future results.

Boston Scientific Corporation (BSX) vs GSK plc (GSK)

A side-by-side comparison of Boston Scientific Corporation and GSK plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 11, 2026. Differences are shown without an overall score or investment verdict.

BSX

Boston Scientific Corporation

$76.09B

$51.19HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT

GSK

GSK plc

$101.98B

$50.90HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT

Total return — BSX vs GSK

growth of $100 · dividends reinvested · last 10y

BSX +111.1% (+7.8%/yr)GSK +88.1% (+6.5%/yr)BSX compounded faster over this window

BSX GSK

BSX vs GSK: by the numbers

•GSK is the larger company ($101.98B vs $76.09B market cap).
•GSK trades at the lower trailing earnings multiple (16.49 vs 20.51 P/E), one valuation lens rather than an overall verdict.
•BSX converts more revenue to profit (17.47% vs 14.52% net margin).
•BSX grew revenue faster over the past five years (13.40% vs 1.38% CAGR).
•GSK pays a dividend (3.44% yield), while BSX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	BSX	GSK
P/E ratio	20.51	16.49
Forward P/E	15.28	14.58
P/S ratio	3.57	2.39
P/B ratio	3.01	4.56
EV / EBITDA	15.01	8.46
FCF yield	4.84%	8.80%

Profitability

Metric	BSX	GSK
Gross margin	71.16%	72.71%
Operating margin	21.46%	20.72%
Net margin	17.47%	14.52%
ROE	14.71%	27.67%
ROIC	8.78%	16.61%

Dividends

Metric	BSX	GSK
Dividend yield	N/A	3.44%
Payout ratio	N/A	47.32%

Growth (annualized)

Metric	BSX	GSK
Revenue CAGR (5Y)	13.40%	1.38%
EPS CAGR (5Y)	N/A	-0.71%
FCF CAGR (5Y)	15.64%	-2.45%
Total return CAGR (5Y)	3.42%	9.56%

Frequently asked

Which has the lower trailing P/E, BSX or GSK?: GSK has the lower trailing P/E: BSX trades at 20.51 and GSK at 16.49. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BSX or GSK?: Over the past five years, BSX grew revenue faster — BSX at a 13.40% CAGR versus GSK at 1.38%.
Does BSX or GSK pay a bigger dividend?: GSK pays a dividend (3.44% yield), while BSX has no payments in the available dividend history.
Is BSX or GSK more profitable?: BSX runs the higher net margin — BSX at 17.47% versus GSK at 14.52%.
How have BSX and GSK total returns compared?: Over the past 10 years, BSX delivered 7.77% and GSK delivered 6.47% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BSX analysis Full GSK analysis Interactive comparison tool

Dig into the metrics

Boston Scientific P/E ratio GSK P/E ratio GSK dividend yield Boston Scientific ROE GSK ROE Boston Scientific operating margin GSK operating margin Boston Scientific revenue growth GSK revenue growth Boston Scientific free cash flow GSK free cash flow

Boston Scientific & GSK appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 11, 2026.